Huaren Pharmaceutical announcement, the company recently received the pharmaceutical registration certificate for sodium hypophosphite injection issued by the National Medical Products Administration. This pharmaceutical is used for cytomegalovirus retinitis in AIDS patients and herpes simplex virus skin and mucous membrane infections in patients with immune function impairment resistant to acyclovir. Sodium hypophosphite injection is a viral inhibitor developed by AstraZeneca, initially used for cytomegalovirus retinitis, and has been marketed in multiple countries. This approval makes Huaren Pharmaceutical the first domestic enterprise to obtain this product approval and pass the consistency evaluation, enriching the company's pharmaceutical product line and optimizing product structure, which has a positive impact on the company's development.